Home > Insider Trading > Filing (0001209191-21-055725)

Filing Details

Accession Number:: 0001209191-21-055725
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2021-09-13 18:22:52
Reporting Period:: 2021-09-09

Accepted Time:: 2021-09-13 18:22:52
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1789972	Cullinan Oncology Inc.	CGEM	()	4

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1134655	Ansbert Gadicke	C/O Mpm Asset Management Llc 450 Kendall Street Cambridge MA 02142		Yes	No	Yes	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Disposition	2021-09-09	1,898	$29.35	248,170	No	4	S	Direct
Common Stock	Disposition	2021-09-09	13,727	$29.35	7,674,449	No	4	S	Indirect	See Footnote
Common Stock	Disposition	2021-09-10	820	$29.04	247,350	No	4	S	Direct
Common Stock	Disposition	2021-09-10	5,931	$29.04	7,668,518	No	4	S	Indirect	See Footnote
Common Stock	Disposition	2021-09-13	497	$29.10	246,853	No	4	S	Direct
Common Stock	Disposition	2021-09-13	3,595	$29.10	7,664,923	No	4	S	Indirect	See Footnote

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	S	Direct
No	4	S	Indirect	See Footnote
No	4	S	Direct
No	4	S	Indirect	See Footnote
No	4	S	Direct
No	4	S	Indirect	See Footnote

Footnotes

Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 on June 23, 2021.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.00 to $29.56 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
These securities are owned directly by UBS Oncology Impact Fund LP ("OIF"). The general partner of OIF is Oncology Impact Fund (Cayman) Management L.P. ("OIF GP"). The general partner of OIF GP is BioImpact Capital LLC. Dr. Ansbert Gadicke is a member of the Issuer's board of directors and is a managing partner of BioImpact Capital LLC.
The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.00 to $29.105 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.00 to $29.26 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.